文献速递膀胱癌与上尿路尿路上皮癌

膀胱癌根治性膀胱切除术后生存率的性别差异:系统综述与荟萃分析

Gender Specific Differences in Disease-Free, Cancer Specific and Overall Survival after Radical Cystectomy for Bladder Cancer: A Systematic Review and Meta-Analysis.
PubMed 文献 · J Urol · 2018-03-01

该系统综述与荟萃分析检索MEDLINE、Embase和Cochrane Library,纳入1998至2017年发表的59项研究,评估膀胱癌根治性膀胱切除术后无病生存、肿瘤特异性生存和总生存的性别差异。随机效应荟萃分析显示女性患者三项生存结局均劣于男性,亚组分析各分层结果一致。

要点

  • 女性膀胱癌根治性膀胱切除术后无病生存、肿瘤特异性生存和总生存均劣于男性。
  • 无病生存HR 1.16(95%CI 1.06-1.27,p=0.0018),肿瘤特异性生存HR 1.23(95%CI 1.15-1.31,p<0.001)。
  • 总生存HR 1.08(95%CI 1.03-1.12,p=0.0004),亚组分析各分层均证实女性生存受损。

核心结论

  • 女性膀胱癌患者根治性膀胱切除术后无病生存、肿瘤特异性生存和总生存均劣于男性。
  • 病因可能是多因素的,包括流行病学差异、性别相关的医疗差异和激素影响。

研究设计与样本

  • 系统综述与荟萃分析,检索MEDLINE、Embase和Cochrane Library(2017年7月)。
  • 共纳入1998至2017年发表的59项研究。
  • 无病生存30项研究共38,321例,肿瘤特异性生存44项研究共69,666例,总生存26项研究共30,039例。
  • 采用随机效应荟萃分析、亚组分析、荟萃影响分析和累积荟萃分析,并用漏斗图和Egger检验评估发表偏倚。

主要发现

  • 随机效应荟萃分析显示女性患者无病生存、肿瘤特异性生存和总生存均低于男性。
  • 无病生存合并HR 1.16(95%CI 1.06-1.27,p=0.0018)。
  • 肿瘤特异性生存合并HR 1.23(95%CI 1.15-1.31,p<0.001)。
  • 总生存合并HR 1.08(95%CI 1.03-1.12,p=0.0004)。
  • 亚组分析在所有分层中均证实女性无病生存、肿瘤特异性生存和总生存受损。

关键数值与推荐

  • 无病生存:30项研究共38,321例患者,合并HR 1.16(95%CI 1.06-1.27,p=0.0018)。
  • 肿瘤特异性生存:44项研究共69,666例患者,合并HR 1.23(95%CI 1.15-1.31,p<0.001)。
  • 总生存:26项研究共30,039例患者,合并HR 1.08(95%CI 1.03-1.12,p=0.0004)。
  • 发表偏倚仅见于肿瘤特异性生存研究(Egger检验p=0.0029);经trim and fill法校正后肿瘤特异性生存合并HR为1.13(95%CI 1.05-1.21,p=0.0012)。

临床怎么用

  • 提示临床对女性膀胱癌患者根治性膀胱切除术后应关注更差的生存结局并加强随访管理。
  • 生存差异的病因涉及流行病学、医疗差异和激素等多因素,需进一步研究以指导性别特异性诊疗。

局限性

  • 肿瘤特异性生存研究存在发表偏倚(Egger检验p=0.0029),校正后合并HR有所变化。
  • 原文未报告各纳入研究的异质性指标及具体随访时长。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We summarize the evidence on gender specific differences in disease-free, cancer specific and overall survival after radical cystectomy for bladder cancer. MATERIALS AND METHODS: We performed a systematic literature search of MEDLINE®, Embase® and the Cochrane Library in July 2017. Studies evaluating gender specific differences in disease-free, cancer specific or overall survival after radical cystectomy for bladder cancer were included in study. Analyses included random effect meta-analysis, subgroup analyses, meta-influence and cumulative meta-analyses. Funnel plots and the Egger test were used to assess publication bias. RESULTS: Of the 3,868 studies identified during the literature search 59 published between 1998 and 2017 were included in analysis. Of the studies 30 in a total of 38,321 patients evaluated disease-free survival, 44 in a total of 69,666 evaluated cancer specific survival and 26 in a total of 30,039 evaluated overall survival. Random effect meta-analyses revealed decreased disease-free, cancer specific survival and overall survival in female patients than in their male counterparts. Pooled estimates showed a HR of 1.16 (95% CI 1.06-1.27, p = 0.0018) for disease-free survival, 1.23 (95% CI 1.15-1.31, p <0.001) for cancer specific survival and 1.08 (95% CI 1.03-1.12, p = 0.0004) for overall survival. Subgroup analyses confirmed impaired disease-free, cancer specific and overall survival in female patients in all strata. Publication bias was evident only for studies of cancer specific survival (Egger test p = 0.0029). After adjusting for publication bias by the trim and fill method the corrected pooled estimated HR of cancer specific survival was 1.13 (95% CI 1.05-1.21, p = 0.0012). CONCLUSIONS: Female patients who underwent radical cystectomy for bladder cancer demonstrated worse disease-free, cancer specific and overall survival than their male counterparts. The multifactorial etiology might include epidemiological differences, gender specific health care discrepancies and hormonal influences.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Uhlig A, Seif Amir Hosseini A, Simon J, et al. Gender Specific Differences in Disease-Free, Cancer Specific and Overall Survival after Radical Cystectomy for Bladder Cancer: A Systematic Review and Meta-Analysis. J Urol. 2018. PMID: 29477716. doi:10.1016/j.juro.2017.11.150

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。